|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108.
2005.PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global CANCER STATISTIcs 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
4
|
Rustum YM: Thymidylate synthase: A
critical target in cancer therapy? Front Biosci. 9:2467–2473. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Awouters F, Megens A, Verlinden M,
Schuurkes J, Niemegeers C and Janssen PAJ: Loperamide: Survey of
studies on mechanism of its antidiarrheal activity. Dig Dis Sci.
38:977–995. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou Y, Sridhar R, Shan L, Sha W, Gu X and
Sukumar S: Loperamide, an FDA-approved antidiarrhea drug,
effectively reverses the resistance of multidrug resistant
MCF-7/MDR1 human breast cancer cells to doxorubicin-induced
cytotoxicity. Cancer Invest. 30:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zielke S, Meyer N, Mari M, Abou-El-Ardat
K, Reggiori F, van Wijk SJL, Kögel D and Fulda S: Loperamide,
pimozide, and STF-62247 trigger autophagy-dependent cell death in
glioblastoma cells. Cell Death Dis. 9:9942018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meyer N, Henkel L, Linder B, Zielke S,
Tascher G, Trautmann S, Geisslinger G, Münch C, Fulda S, Tegeder I
and Kögel D: Autophagy activation, lipotoxicity and lysosomal
membrane permeabilization synergize to promote pimozide- and
loperamide-induced glioma cell death. Autophagy. 17:3424–3443.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang JC, Feng YL, Liang X and Cai XJ:
Autophagy in 5-fluorouracil therapy in gastrointestinal cancer:
Trends and challenges. Chin Med J (Engl). 129:456–563. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang BR, Han JB, Jiang Y, Xu S, Yang R,
Kong YG, Tao ZZ, Hua QQ, Zou Y and Chen SM: CENPN suppresses
autophagy and increases paclitaxel resistance in nasopharyngeal
carcinoma cells by inhibiting the CREB-VAMP8 signaling axis.
Autophagy. 20:329–348. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnston PG, Drake JC, Trepel J and
Allegra CJ: Immunological quantitation of thymidylate synthase
using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive
and -resistant human cancer cell lines. Cancer Res. 52:4306–4312.
1992.PubMed/NCBI
|
|
13
|
Copur S, Aiba K, Drake JC, Allegra CJ and
Chu E: Thymidylate synthase gene amplification in human colon
cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol.
49:1419–1426. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baker DE: Loperamide: A pharmacological
review. Rev Gastroenterol Disord. 7 (Suppl 3):S11–S18.
2007.PubMed/NCBI
|
|
15
|
Parkar N, Spencer NJ, Wiklendt L, Olson T,
Young W, Janssen P, McNabb WC and Dalziel JE: Novel insights into
mechanisms of inhibition of colonic motility by loperamide. Front
Neurosci. 18:14249362024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu PE and Juurlink DN: Clinical review:
Loperamide toxicity. Ann Emerg Med. 70:245–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu J, Guo Q, Li J, Yuan H, Xiao C, Qiu J,
Wu Q and Wang D: Loperamide induces protective autophagy and
apoptosis through the ROS/JNK signaling pathway in bladder cancer.
Biochem Pharmacol. 218:1158702023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Regan RC, Gogal RM Jr, Barber JP,
Tuckfield RC, Howerth EW and Lawrence JA: Cytotoxic effects of
loperamide hydrochloride on canine cancer cells. J Vet Med Sci.
76:1563–1568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim IY, Shim MJ, Lee DM, Lee AR, Kim MA,
Yoon MJ, Kwon MR, Lee HI, Seo MJ, Choi YW and Choi KS: Loperamide
overcomes the resistance of colon cancer cells to bortezomib by
inducing CHOP-mediated paraptosis-like cell death. Biochem
Pharmacol. 162:41–54. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tong CWS, Wu MMX, Yan VW, Cho WCS and To
KKW: Repurposing loperamide to overcome gefitinib resistance by
triggering apoptosis independent of autophagy induction in KRAS
mutant NSCLC cells. Cancer Treat Res Commun.
25:1002292020.PubMed/NCBI
|
|
21
|
Yang S, Li Z, Pan M, Ma J, Pan Z, Zhang P
and Cao W: Repurposing of antidiarrheal loperamide for treating
melanoma by inducing cell apoptosis and cell metastasis suppression
in vitro and in vivo. Curr Cancer Drug Targets. 24:1015–1030. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roncuzzi L, Perut F and Baldini N:
Repurposing of loperamide as a new drug with anticancer activity
for human osteosarcoma. Anticancer Res. 44:1063–1070. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang T, Song X, Yang Y, Wan X, Alvarez
AA, Sastry N, Feng H, Hu B and Cheng SY: Autophagy and hallmarks of
cancer. Crit Rev Oncog. 23:247–267. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh SS, Vats S, Chia AYQ, Tan TZ, Deng
S, Ong MS, Arfuso F, Yap CT, Goh BC, Sethi G, et al: Dual role of
autophagy in hallmarks of cancer. Oncogene. 37:1142–1158. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yun CW, Jeon J, Go G, Lee JH and Lee SH:
The dual role of autophagy in cancer development and a therapeutic
strategy for cancer by targeting autophagy. IJMS. 22:1792020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang H and Zou Z: Targeting autophagy to
overcome drug resistance: Further developments. J Hematol Oncol.
13:1592020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu F, Song D, Yan Y, Huang C, Shen C, Lan
J, Chen Y, Liu A, Wu Q, Sun L, et al: IL-6 regulates autophagy and
chemotherapy resistance by promoting BECN1 phosphorylation. Nat
Commun. 12:36512021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Reyes-Castellanos G, Abdel Hadi N and
Carrier A: Autophagy contributes to metabolic reprogramming and
therapeutic resistance in pancreatic tumors. Cells. 11:4262022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen C, Lu L, Yan S, Yi H, Yao H, Wu D, He
G, Tao X and Deng X: Autophagy and doxorubicin resistance in
cancer. Anticancer Drugs. 29:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu T, Guo F, Yu Y, Sun T, Ma D, Han J,
Qian Y, Kryczek I, Sun D, Nagarsheth N, et al: Fusobacterium
nucleatum promotes chemoresistance to colorectal cancer by
modulating autophagy. Cell. 170:548–563.e16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng Z, Zhang S, Han Q, Chu T, Wang H, Yu
L, Zhang W, Liu J, Liang W, Xue J, et al: Liensinine sensitizes
colorectal cancer cells to oxaliplatin by targeting HIF-1α to
inhibit autophagy. Phytomedicine. 129:1556472024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Z, Chen H, Huang L, Duan B, Dai S,
Cai W, Sun M, Jiang Z, Lu R, Jiang Y, et al: ATB°,+-targeted
nanoparticles initiate autophagy suppression to overcome
chemoresistance for enhanced colorectal cancer therapy. Int J
Pharm. 641:1230822023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang R, Pan T, Xiang Y, Zhang M, Feng J,
Liu S, Duan T, Chen P, Zhai B, Chen X, et al: β-Elemene reverses
the resistance of p53-deficient colorectal cancer cells to
5-fluorouracil by inducing pro-death autophagy and cyclin
D3-dependent cycle arrest. Front Bioeng Biotechnol. 8:3782020.
View Article : Google Scholar : PubMed/NCBI
|
